Laverdia vs. Tanovea: Key Differences in Canine Lymphoma Treatment
A diagnosis of lymphoma can stop dog parents in their tracks. Whether you’re facing this for the first time or you’ve already walked this road with a beloved canine cancer warrior, one thing becomes clear very quickly: treatment decisions matter and options matter.
In recent years, veterinary oncology has continued to evolve, and a newly FDA-approved drug called Laverdia™ represents an important step forward. At the same time, another medication, Tanovea-CA1®, has already been helping dogs with lymphoma in specific situations.
Here’s what dog parents need to know about both treatments, how they differ, and what this progress means for dogs diagnosed today.
Understanding Canine Lymphoma
Lymphoma is one of the most common cancers diagnosed in dogs. It affects the lymphatic system and often progresses quickly without treatment. While lymphoma is rarely curable, many dogs can achieve meaningful remission and maintain good quality of life with appropriate care.
Treatment plans are individualized and may include chemotherapy, targeted drugs, or palliative care depending on the dog’s health, cancer type, and family goals.
What Is Laverdia™?
Laverdia (generic name: verdinexor) is the first FDA-approved oral medication specifically approved for the treatment of canine lymphoma.
Unlike traditional chemotherapy drugs that require IV administration at a veterinary clinic, Laverdia is given by mouth, typically at home, under veterinary supervision.
Laverdia works by inhibiting a protein called XPO1, which cancer cells rely on to survive and multiply. By blocking this pathway, the drug helps slow lymphoma progression.
Why Laverdia’s FDA Approval Matters
The approval, granted by the U.S. Food and Drug Administration, is significant because it:
Confirms safety and effectiveness through regulated clinical trials
Marks the first oral FDA-approved treatment for canine lymphoma
Expands treatment options beyond injectable chemotherapy
Laverdia does not replace chemotherapy for all dogs, but it adds an important new category of care.
What Is Tanovea-CA1®?
Tanovea-CA1 (rabacfosadine) is another FDA-recognized drug used in the treatment of canine lymphoma.
Tanovea:
Is administered intravenously (IV) by a veterinarian
Is classified as a chemotherapy drug
Has received conditional FDA approval for treating lymphoma in dogs
It is often used:
As a single-agent treatment
In dogs whose lymphoma has relapsed
When standard multi-drug chemotherapy is not an option
Tanovea has been an important tool for veterinary oncologists, particularly in rescue or alternative treatment settings.
Laverdia vs. Tanovea: Key Differences
Here’s a clear comparison to help dog parents understand how these two drugs differ:
| Feature | Laverdia™ | Tanovea-CA1® |
|---|---|---|
| FDA status | Full FDA approval | Conditional FDA approval |
| Administration | Oral (at home) | Injectable (IV, in clinic) |
| Drug type | Targeted small-molecule inhibitor | Chemotherapy |
| Vet visits | Fewer required | Regular clinic visits |
| Role in treatment | New option, quality-of-life focused | Established lymphoma option |
Both drugs can be effective in the right circumstances and neither is automatically “better” than the other.
Which Treatment Is Right for a Dog With Lymphoma?
The best treatment depends on several factors, including:
Stage and type of lymphoma
The dog’s overall health and age
Prior cancer treatments
Family preferences and quality-of-life goals
Some dogs may do well with traditional chemotherapy. Others may benefit from newer options like Laverdia or drugs like Tanovea. Many treatment decisions are guided by a veterinary oncologist, who can help tailor care to each individual dog.
What This Means for Dog Parents
For families facing lymphoma today, the approval of Laverdia means more choice, more flexibility, and continued progress in canine cancer care.
For families who have already lost a dog to lymphoma, it represents something equally important: proof that research, advocacy, and awareness continue to push treatment forward so future dogs may have better options and better days.
Canine cancer care is evolving, and every new approved treatment brings us closer to more personalized, compassionate options for dogs and the people who love them.
Recent Comments